Abstract
Introduction
A retrospective review of therapeutic plasma exchange (TPE) for vasculitis of any form during the period 1993–2003 was carried out in our unit.
Subjects and methods
The case histories of 32 children undergoing TPE were analysed to determine short-term outcome. The vasculitides consisted of polyarteritis nodosa (PAN), ANCA-associated vasculitis (AAV) [encompassing Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA)/idiopathic crescentic nephritis (ICN)], Henoch-Schönlein purpura (HSP) and non-classified vasculitis (NCV).
Results
All children with PAN (n=5) had a good response to treatment except for one with gastro-intestinal symptoms. One child was treated for crescentic nephritis, with 42% crescents seen on biopsy. The estimated glomerular filtration rate (eGFR) (Schwartz formula) for this child improved from 81 to 130 ml/min/1.73 m2 post-treatment. Inflammatory markers decreased immediately following TPE and were maintained at the lower level for all the children. Ten children (n=12) with AAV received treatment for renal manifestations. Median creatinine clearances improved from 29 ml/min/1.73 m2 (p<0.01) pre-treatment to 62 ml/min/1.73 m2 (p<0.01) immediately following TPE and 69 ml/min/1.73 m2 at 2 months post-TPE (p<0.01). Four children required dialysis; one child remained dialysis-dependent and one child progressed to chronic renal failure. Inflammatory markers decreased following TPE. All of the children with HSP (n=5) were treated for crescentic nephritis. Two regained normal renal function, and one became dialysis-dependent later. Most of the children with NCV (n=10) presented with CNS or general vasculitic features, with the greatest benefit for CNS symptoms.
Conclusions
In our experience TPE appears to be of benefit during the acute phase of illness, especially in children with organ-specific disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K (1992) A prospective randomised trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 20:261–269
de Groot K, Jayne D (2005) What is new in the therapy of ANCA-associated vasculidites? Take home message from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 64:480–484
Frasca GM, Zoumparidis NG, Borgnino LC, Neri L, Vangelista A, Bonomini V (1991) Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodies. Int J Artif Organs 15:181–184
Frasca GM, Zoumparidis NG, Borgnino LC, Neri L, Neri L, Vangelista A, Bonomini V (1993) Combined treatment in Wegener’s granulomatosis with crescentic glomerulonephritis-clinical and long-term outcome. Int J Artif Organs 16:11–19
Gianviti A, Trompeter RS, Barratt TM, Lythgoe MF, Dillon MJ (1996) Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child 75:186–190
Guillevin L, Fain O, Lhote F , Jarrousse B, Le Thi Huong D, Bussel A, Leon A (1992) Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35:208–215
Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, Leon A, Bussel A (1995) Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective randomized trial in sixty-two patients. Arthritis Rheum 38:1638–1645
Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT (1990) The American College of Rheumatology criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067
Jardim HM, Leake J, Risdon RA, Barratt TM, Dillon MJ (1992) Crescentic glomerulonephritis in children. Pediatr Nephrol 6:231–235
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192
Jones JV, Bucknall RC, Cumming RH, Asplin CM (1976) Plasmapheresis in the management of acute systemic lupus erythematosus. Lancet 2:709–711
Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, Suzuki S, Suzuki H (2004) Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis. Pediatr Nephrol 19:920–923
Lockwood CM, Pinching AJ, Sweny P (1977) Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 8:63–67
Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM (1991) Plasma exchange in focal necrotising glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757–763
Roberti I, Reisman L, Churg J (1993) Vasculitis in childhood. Pediatr Nephrol 7:479–489
Schärer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F (1999) Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol 13: 816–823
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wright, E., Dillon, M.J. & Tullus, K. Childhood vasculitis and plasma exchange. Eur J Pediatr 166, 145–151 (2007). https://doi.org/10.1007/s00431-006-0212-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-006-0212-2